Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Akero Therapeutics's share price for the quarter that ended in Dec. 2023 was $23.35. Akero Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 55.75 Mil. Therefore, Akero Therapeutics's market cap for the quarter that ended in Dec. 2023 was $1,301.87 Mil.
Akero Therapeutics's quarterly market cap
increased
from Jun. 2023 ($2,593.54 Mil) to Sep. 2023 ($2,816.34 Mil) but then
declined
from Sep. 2023 ($2,816.34 Mil) to Dec. 2023 ($1,301.87 Mil).
Akero Therapeutics's annual market cap
increased
from Dec. 2021 ($738.15 Mil) to Dec. 2022 ($2,568.21 Mil) but then
declined
from Dec. 2022 ($2,568.21 Mil) to Dec. 2023 ($1,301.87 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Akero Therapeutics's Enterprise Value for Today is $909.71 Mil.
Akero Therapeutics Market Cap Historical Data
The historical data trend for Akero Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Akero Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akero Therapeutics Market Cap Distribution
For the Biotechnology industry and Healthcare sector, Akero Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Akero Therapeutics's Market Cap falls into.
Akero Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Akero Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics (NAS:AKRO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Akero Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Akero Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Akero Therapeutics (Akero Therapeutics) Business Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKRO has been successfully added to your 